The REMoDL-B trial tested R-CHOP vs. R-CHOP + bortezomib (RB-CHOP) in newly diagnosed DLBCL patients stratified by cell of origin [15,16] and documented a significantly improved 5-year overall and progression-free survival for ABC- and MHG-DLBCL patients treated with bortezomib in combination with R-CHOP [16]. The gene discussed is DDIT3; the disease is diffuse large B-cell lymphoma.